Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 24, showing 5 Applications out of 117 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/18/01/01   Mal 094
    Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age.   
Principal Investigator(s)
1. Aaron Samuels
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral hospital (Siaya county)
2. Ngiya Health Center (Siaya county)
3. Kogelo Health Center (Siaya county)
4. Tingwangi (Siaya county)
5. Mulaha (Siaya county)
6. Nyathengo (Siaya county)
7. Bal Olengo (Siaya county)
 
View

17.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

18.

ECCT/20/11/02   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing  Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and   African Adults (IAVI C100)   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county)
2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county)
 
View

19.

ECCT/18/07/01   CCNO17 Male contraception study.
    Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception.       
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
Couples counselling Center
 
View

20.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
View